Publications and communications of Laetitia Montero-Ruiz

Pottier, C., Montero-Ruiz, L., Noël, A., Jerusalem, G., & Sounni, N. E. (June 2022). Non genetic mechanisms of ER+ HER2- breast cancer resistance to the combination of Palbociclib and Fulvestrant [Poster presentation]. The European Association for Cancer Research Congress, Seville, Spain.

Luis, G.* , Godfroid, A.* , Nishiumi, S., Cimino, J., Blacher, S., Maquoi, E., Wery, C., Collignon, A., Longuespée, R., MONTERORUIZ, L., Dassoul, I., Maloujahmoum, N., Pottier, C., Mazzucchelli, G., De Pauw, E., Bellahcene, A., Yoshida, M., Noël, A., & Sounni, N. E. (2021). Tumor resistance to ferroptosis driven by Stearoyl-CoA Desaturase-1 (SCD1) in cancer cells and Fatty Acid Biding Protein-4 (FABP4) in tumor microenvironment promote tumor recurrence. Redox Biology, 43, 102006. doi:10.1016/j.redox.2021.102006
* These authors have contributed equally to this work.

FOIDART, P., Yip, C., Radermacher, J., Blacher, S., Lienard, M., MONTERORUIZ, L., Maquoi, E., Montaudon, E., Chateau-Joubert, S., COLLIGNON, J., Coibion, M., Jossa, V., Marangoni, E., Noël, A., Sounni, N. E.* , & JERUSALEM, G.*. (2019). Expression of MT4-MMP, EGFR, and RB in Triple-Negative Breast Cancer Strongly Sensitizes Tumors to Erlotinib and Palbociclib Combination Therapy. Clinical Cancer Research. doi:10.1158/1078-0432.CCR-18-1880
* These authors have contributed equally to this work.

FOIDART, P., Yip, C., Radermacher, J., MONTERORUIZ, L., Coibion, M., Jossa, V., Marangoni, E., Noël, A., Sounni, N. E., & JERUSALEM, G. (24 February 2018). MT4-MMP, EGFR and RB expressions are predictive biomarkers of response to Erlotinib-Palbociclib combination in TNBC [Paper presentation]. Belgian Society of Medical Oncology: annual meeting, Ostende, Belgium.

FOIDART, P., Yip, C., Radermacher, J., MONTERORUIZ, L., Marangoni, E., Noël, A., Sounni, N. E., JERUSALEM, G., Coibion, M., Jossa, V., & BLACHER, S. (27 January 2018). Expression of MT4-MMP, EGFR and Rb in triple negative breast cancers strongly sensitizes tumors to Erlotinib and Palbociclib combination therapy [Paper presentation]. Belgian Association for Cancer Research : Annual Meeting, Liège, Belgium.